MX2023008865A - Pirrolopirimidina y pirazolopirimidina sustituidas como degradadores de tirosina cinasa de bruton (btk). - Google Patents

Pirrolopirimidina y pirazolopirimidina sustituidas como degradadores de tirosina cinasa de bruton (btk).

Info

Publication number
MX2023008865A
MX2023008865A MX2023008865A MX2023008865A MX2023008865A MX 2023008865 A MX2023008865 A MX 2023008865A MX 2023008865 A MX2023008865 A MX 2023008865A MX 2023008865 A MX2023008865 A MX 2023008865A MX 2023008865 A MX2023008865 A MX 2023008865A
Authority
MX
Mexico
Prior art keywords
btk
bruton
tyrosine kinase
degraders
pyrazolopyrimidine
Prior art date
Application number
MX2023008865A
Other languages
English (en)
Spanish (es)
Inventor
Yimin Qian
Jie Su
Ke Liu
Wei He
Jie Fan
Robert Luo
Hui Zhang
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Publication of MX2023008865A publication Critical patent/MX2023008865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023008865A 2021-02-03 2022-02-02 Pirrolopirimidina y pirazolopirimidina sustituidas como degradadores de tirosina cinasa de bruton (btk). MX2023008865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163145126P 2021-02-03 2021-02-03
PCT/US2022/014830 WO2022169798A2 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders

Publications (1)

Publication Number Publication Date
MX2023008865A true MX2023008865A (es) 2023-08-31

Family

ID=80447078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008865A MX2023008865A (es) 2021-02-03 2022-02-02 Pirrolopirimidina y pirazolopirimidina sustituidas como degradadores de tirosina cinasa de bruton (btk).

Country Status (11)

Country Link
US (2) US11530222B2 (cg-RX-API-DMAC7.html)
EP (2) EP4501327A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024505558A (cg-RX-API-DMAC7.html)
KR (1) KR20230142539A (cg-RX-API-DMAC7.html)
CN (1) CN117042769A (cg-RX-API-DMAC7.html)
CA (1) CA3209082A1 (cg-RX-API-DMAC7.html)
DK (1) DK4039688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3010513T3 (cg-RX-API-DMAC7.html)
FI (1) FI4039688T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023008865A (cg-RX-API-DMAC7.html)
WO (1) WO2022169798A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
EP4452945A2 (en) * 2021-12-20 2024-10-30 Sigma-Aldrich Co. LLC Chemical linkers
WO2023235691A1 (en) * 2022-05-31 2023-12-07 Accutar Biotechnology, Inc. Btk reducing molecules for treatment of cancers and immune system disorders
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
CN120051475A (zh) * 2023-05-26 2025-05-27 广东弘烨医药科技有限公司 9元杂芳基化合物、含其的药物组合物及其制备方法和应用
KR20260041885A (ko) 2023-07-25 2026-03-27 몬테 로사 테라퓨틱스 아게 표적화된 단백질 분해를 위한 치환된 피페리딘디온
CN120535526A (zh) * 2024-02-26 2025-08-26 中国药科大学 直接结合蛋白酶体的非泛素依赖型蛋白水解靶向嵌合体NuTAC及其应用
WO2026040951A1 (zh) * 2024-08-19 2026-02-26 深圳市塔吉瑞生物医药股份有限公司 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
US10611766B2 (en) * 2015-09-16 2020-04-07 Loxo Oncology Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
AU2017315343A1 (en) * 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2019177902A1 (en) * 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112979656A (zh) * 2019-12-12 2021-06-18 上海美志医药科技有限公司 一类靶向降解btk蛋白的化合物

Also Published As

Publication number Publication date
EP4039688A2 (en) 2022-08-10
JP2024505558A (ja) 2024-02-06
KR20230142539A (ko) 2023-10-11
WO2022169798A2 (en) 2022-08-11
ES3010513T3 (en) 2025-04-03
FI4039688T3 (fi) 2024-12-19
EP4039688B1 (en) 2024-10-09
CA3209082A1 (en) 2022-08-11
EP4039688A3 (en) 2022-11-23
US20240132502A1 (en) 2024-04-25
EP4501327A3 (en) 2025-10-15
WO2022169798A3 (en) 2022-09-22
EP4501327A2 (en) 2025-02-05
DK4039688T3 (da) 2025-01-02
US11530222B2 (en) 2022-12-20
CN117042769A (zh) 2023-11-10
US20220259207A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
WO2022169798A3 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
GEP20063734B (en) Beta-Amino Tetrahydroimidazo (1, 2-A)Pyrazines And Tetrahydrotrioazolo (4, 3-A)Pyrazines as Dipeptidyl Peptidase Inhibitors for Treatment or Prevention of Diabetes
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
MX2022001690A (es) Compuestos deuterados para usarse en el tratamiento del cancer.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2018226622A8 (en) Compounds for treating huntington's disease
DE60330485D1 (de) Zur behandlung von diabetes
GEP20257840B (en) Tyk2 pseudokinase ligands
PH12022553019A1 (en) Il-17a modulators
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
TW200635588A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
PH12022500021A1 (en) Il-17a modulators
MX2024011254A (es) Moduladores de nlrp3
MX2024007328A (es) Inhibidores macrociclicos de btk.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12022552447A1 (en) Nlrp3 modulators
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
MX2025004094A (es) Inhibidores y/o degradadores de hsd17b13
MX2025014163A (es) Azinas condensadas como inhibidores de tyk2 y usos de las mismas
MX2024015127A (es) Compuestos triciclicos de triazolo como inhibidores de la diacilglicerol cinasa (dgk)